首页> 外文OA文献 >Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.

【2h】

Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.

机译：Mericitabine和Boceprevir或Telaprevir或Peginterferon Alfa-2a加Ribavirin联合治疗慢性丙型肝炎基因1型感染和先前无效反应的患者：DYNAMO 1和DYNAMO 2随机研究。

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Wedemeyer Heiner; Forns Xavier; Hézode Christophe; Lee Samuel S; Scalori Astrid; Voulgari Athina; Le Pogam Sophie; Nájera Isabel; Thommes James A;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response [J] . VierlingJ.M., DavisM., FlammS., Journal of Hepatology: The Journal of the European Association for the Study of the Liver . 2014,第4期

机译：Boceprevir用于先前接受聚乙二醇干扰素/利巴韦林治疗失败，包括先前无效反应的患者的慢性HCV基因型1感染
2. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial [J] . Reddy K. Rajender, Zeuzem Stefan, Zoulim Fabien, The Lancet infectious diseases . 2015,第1期

机译：Simeprevir与telaprevir联合聚乙二醇干扰素和利巴韦林在先前无效或部分应答的慢性丙型肝炎病毒基因型1感染（ATTAIN）中的研究：一项随机，双盲，非劣效性3期试验
3. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. [J] . Ferenci P, Formann E, Laferl H, Journal of Hepatology: The Journal of the European Association for the Study of the Liver . 2006,第2期

机译：peginterferon alfa-2a（40KD）加利巴韦林加金刚烷胺或不加金刚烷胺的随机，双盲，安慰剂对照研究在未经治疗的慢性丙型肝炎基因1型患者中进行。
4. Predictability of Sustained Virological Response (SVR) in Patients with HCV/HIV Co-infection During Combination Therapy With Peginterferon Alfa-2A (40KD) (PEGASYS~R) Plus Ribavirin (COPEGUS~R) in the APRICOT Trial [C] . M. Rodriguez Torres, F.J. Torriani, E. Lissen International AIDS Conference . 2004

机译：HCV / HIV与Peginterferon Alfa-2a（40KD）（Pegasys〜R）加上利韦韦林（Copegus〜R）在杏试验期间HCV / HIV CONOMENT患者持续病毒学反应（SVR）的可预测性
5. Population pharmacokinetics and efficacy of ribavirin in patients with chronic hepatitis C genotype 1 infection. [D] . Jin, Runyan. 2010

机译：利巴韦林在慢性丙型肝炎基因型1感染患者中的群体药代动力学和功效。
6. Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies [O] . Heiner Wedemeyer, Xavier Forns, Christophe Hézode, 2011

机译：Mericitabine和Boceprevir或Telaprevir与Peginterferon Alfa-2a加Ribavirin联合治疗慢性丙型肝炎基因1型感染和先前无效反应的患者：DYNAMO 1和DYNAMO 2随机研究
7. Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. [O] . Heiner Wedemeyer, Xavier Forns, Christophe Hézode, 2016

机译：mericitabine和Boceprevir或Telaprevir联合聚乙二醇干扰素α-2a加利巴韦林治疗慢性丙型肝炎患者的基因型1感染和先前的无反应：随机DYNamO 1和DYNamO 2研究。

Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.

著录项

相似文献

相关主题

期刊订阅